Table 1.
Baseline characteristics of patients with and without bacterial infection among patients with fever after TACE and/or RFA.
| Characteristics | Patients with fever after TACE and/or RFA | ||
|---|---|---|---|
| With bacterial infection (N = 9) | Without bacterial infection (N = 88) | P value | |
| Male | 7 (78) | 67 (76) | >0.999 |
| Age∗ | 73 (61–78) | 63 (57–72) | 0.072 |
| Comorbidities | |||
| Diabetes | 4 (44) | 32 (36) | 0.723 |
| Chronic lung disease | 0 (0.0) | 1 (1) | >0.999 |
| Chronic kidney disease | 0 (0.0) | 13 (14.8) | 0.603 |
| Etiology of liver cirrhosis | |||
| HBV | 5 (56) | 53 (61) | 0.863 |
| HCV | 1 (11) | 15 (17) | |
| Both HBV and HCV | 0 (0) | 2 (2) | |
| Alcohol | 3 (33) | 17 (19) | |
| Unknown etiology | 0 (0) | 1 (1) | |
| Child-Pugh score | |||
| A | 7 (78) | 78 (89) | 0.308 |
| B | 2 (22) | 10 (11) | |
| C | 0 (0) | 0 (0) | |
| Ascites | 3 (33) | 10 (11) | 0.099 |
| Previous variceal bleeding | 2 (22) | 6 (7) | 0.160 |
| Previous hepatectomy | 0 (0) | 6 (7) | >0.999 |
| TNM stage | |||
| I | 2 (22) | 21 (24) | 0.103 |
| II | 3 (33) | 42 (48) | |
| IIIA | 0 (0) | 14 (16) | |
| IIIB | 4 (44) | 9 (10) | |
| IVA | 0 (0) | 1 (1) | |
| IVB | 0 (0) | 1 (1) | |
| Number of tumor | |||
| Solitary | 2 (22) | 24 (27) | >0.999 |
| Multiple | 7 (78) | 64 (73) | |
| Intervention | |||
| TACE | 7 (78) | 59 (67) | 0.847 |
| RFA | 1 (11) | 21 (24) | |
| Sequential TACE and RFA | 1 (11) | 8 (9) | |
| Total dose of injected Adriamycin (mg)∗ | 20.0 (20–20)† | 20.0 (20–20)‡ | 0.780 |
| TDD | 26.5 (25–30)† | 26.0 (25–30)‡ | 0.911 |
∗Expressed as median (interquartile range); †8 patients of TACE; ‡68 patients. TACE: transarterial chemoembolization; RFA: radiofrequency ablation; TDD: total dose delivered of TACE (Adriamycin (mg) + dose of iodized oil (mL)); HBV: hepatitis B virus; HCV: hepatitis C virus.